Review Article
The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy
Table 1
The HH signaling pathway inhibitors.
| | Inhibitor Name | Organization | Clinical Trial |
| | (1) SMO inhibitors | | | | Cyclopamine, KAAD-cyclopamine | — | No | | GDC-0449 (Vismodegib/Erivedge) | Roche/Genentech/Curis | Yes (phases 0, I, and II) | | LDE225 (Erismodegib/Sonidegib/Odomzo) | Novartis | Yes (phases 0, I, and II) | | BMS-833923/XL139 | Bristol Myers Squibb/Exelixis | Yes (phases I and II) | | PF-04449913 (Glasdegib) | Pfizer | Yes (Phase II) | | PF-527857 | Pfizer | No | | LY2940680 (Taladegib) | Ignyta | Yes (phases I and II) | | IPI-926 (Sadegib) | Infinity | Yes (phase I) | | TAK-441 | — | No | | MRT-92 | — | No | | (2) GLI inhibitors | | | | GANT-58, GANT-61 | — | No | | Arsenic trioxide (ATO) | — | Yes (phases I, II, III, and IV) | | HPI-1 | — | No | | Glabrescione B (GlaB) | — | No |
|
|
See [14] for description of the clinical trials of HH signaling pathway inhibitors.
|
